Cellectis S.A. (ALCLS.PA)
| Previous close | 2.6600 |
| Open | 2.6450 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's range | 2.5550 - 2.6500 |
| 52-week range | 0.8880 - 3.4400 |
| Volume | |
| Avg. volume | 95,997 |
| Market cap | 185.285M |
| Beta (5Y monthly) | 3.12 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Insider Monkey
Cellectis S.A. (NASDAQ:CLLS) Q3 2023 Earnings Call Transcript
Cellectis S.A. (NASDAQ:CLLS) Q3 2023 Earnings Call Transcript November 7, 2023 Operator: Good morning, everyone, and welcome to the Cellectis Third Quarter 2023 Earnings Calls. [Operator Instructions]. I’d now like to introduce the first speaker Arthur Stril, Chief Business Officer. You may begin. Arthur Stril: Good morning, and welcome, everyone, to Cellectis third quarter 2023 […]
- Reuters
AstraZeneca to invest $245 million in Cellectis to boost gene therapy prospects
Cellectis' gene-editing technology and manufacturing capabilities to design novel cell and gene therapy products will help strengthen AstraZeneca's growing offering in the space, it said. AstraZeneca said that as part of the deal, it will pay Cellectis $105 million by the end of this year. That includes an $80 million equity investment, which will be followed by another $140 million in early 2024, which will give AstraZeneca a stake of about 44% in the French company.
